Oxygen Biotherapeutics Inc.

EANS-News: Oxygen Biotherapeutics Inc.
Now Marketing New Formulation of Dermacyte Oxygen Concentrate

@@start.t1@@--------------------------------------------------------------------------------   Corporate news transmitted by euro adhoc. The issuer/originator is solely   responsible for the content of this announcement. --------------------------------------------------------------------------------@@end@@

Company Information/Marketing/New Products/Biotechnology

Durham, NC (euro adhoc) - Press Release

Oxygen Biotherapeutics Inc.:

Oxygen Biotherapeutics Now Marketing New Formulation of Dermacyte Oxygen Concentrate

DURHAM, NC —Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT) today announced that the company has begun distribution for its newly formulated Dermacyte Oxygen Concentrate for the beauty and skin care market. The over-the-counter product is a scientifically designed perfluorocarbon concentrate designed to enhance oxygen delivery to skin. As of later this week, retail orders also can be placed on the Dermacyte secure website at www.BuyDermacyte.com.

"Inventory of Dermacyte sold out quickly last fall when it was originally introduced in a market test designed to gauge customer interest and response," said Chris Stern, company chairman and CEO. "The feedback we received from customers was quite positive. We´ve improved the Dermacyte concentrate to be smoother and more effective. Therefore, we believe that our new cosmetic line has the potential to be a significant financial contributor to our company."

Dermacyte Oxygen Concentrate is the first product in a broad and diverse cosmetic line currently under development.  It uses the company´s patented Oxycyte technology, an oxygen carrier scientifically designed to enhance oxygen delivery to tissues such as skin. Some potential benefits of increased oxygenation to the skin include a decrease in the appearance of fine lines, wrinkles and dryness.

About Oxygen Biotherapeutics, Inc.

Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and Defense Medicine. The company has developed a perfluorocarbon (PFC) therapeutic oxygen carrier and liquid ventilation product (Oxycyte) and has out-licensed an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs as well as medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including traumatic brain injury, sickle cell crisis, trauma, wound care, decompression sickness, acute respiratory distress syndrome, stroke, myocardial infarction, surgery, diabetes wounds and ulcers, and cosmetic applications which are being marketed under the Dermacyte name. More information is available at www.oxybiomed.com.

Caution Regarding Forward-Looking Statements.

This news release contains certain forward-looking statements by the company that involve risks and uncertainties and reflect the company's judgment as of the date of this release. These statements include those referring to the plans for the expansion of the Dermacyte product line and the timing of the introduction of those new products. Matters beyond the company´s control could lead to delays in the in the new product introductions and customer acceptance of these new products. Furthermore, there can be no assurance that such plans will lead to meaningful sales of Dermacyte or generate any revenue for the company. The company disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

DURHAM, NC  — March 29, 2010

Links

Homepage: www.oxybiomed.com/ Dermacyte: http://www.buydermacyte.com

@@start.t2@@end of announcement                                                 euro adhoc
--------------------------------------------------------------------------------@@end@@

ots Originaltext: Oxygen Biotherapeutics Inc.
Im Internet recherchierbar: http://www.presseportal.ch

Further inquiry note:
Ellen Corliss      
Oxygen Biotherapeutics, Inc.
2530 Meridian Pkwy, 3rd floor        
Durham, NC 27713
Direct Telephone: +1 919 806 4405        
Direct Fax: +1 919 806 4417
Email: e.corliss@oxybiomed.com

Branche: Biotechnology
ISIN:      US69207P2092
WKN:        A0YD9Z
Börsen:  New York / Nasdaq



Weitere Meldungen: Oxygen Biotherapeutics Inc.

Das könnte Sie auch interessieren: